Advancing Precision Diagnostics and Targeted Therapeutics for TBI

Cohen Veterans Bioscience (CVB) is committed to advancing research, advocacy and policy initiatives to improve the lives of people suffering from TBI.

BRAIN TRAUMA BLUEPRINT (BTB)
Fostering collaboration to advance solutions for TBI

The purpose of the BTB roadmap, which involved researchers and other multisector stakeholders, is to advance precision therapeutics for survivors of brain trauma by identifying major gaps in research.

In 2019, we hosted a State of the Science Summit to build consensus on potential paths to TBI treatment and the need to change classifications of mild TBI - due to the heterogeneity of injuries - from mild, moderate and severe to a mechanism-based approach. The resulting recommendations informed actionable research priorities to guide policy decisions and accelerate the development of a new generation of diagnostics and therapeutics.

Learn more: https://www.braintraumablueprint.org

RAPID-Dx
Discovering and validating biomarkers

Research Alliance for Precision, Innovation, and Discovery Diagnostics (RAPID-Dx) is collecting data and performing studies to discover and replicate biomarkers. It also qualifies successful, relevant candidates for development as clinical diagnostics. RAPID-Dx is bringing together large, well-characterized cohort studies, starting with PTSD and TBI.

To accelerate the biomarker discovery process, investigators share large biomarker and imaging legacy datasets in a centralized, cloud-based data platform - BRAIN Commons.

RAPID-Dx will also support the large-scale analysis of stored biosamples on high-precision bioassay platforms. This will generate data for well-powered, multimodal biomarker discovery and assist with systems biology modeling of disease.

Learn more: https://bit.ly/2QkxpXV
NEUROTRAUMA REPORTS NULL HYPOTHESIS
A special collection of articles that will be published to foster data transparency in TBI research

CVB is supporting Neurotrauma Reports Null Hypothesis, a partnership with the Center for Biomedical Research Transparency and Neurotrauma Reports.

This collaborative initiative is dedicated to publishing well-performed negative studies, or studies where the outcomes do not confirm the expected results or working hypotheses, with a focus on null or replication results in TBI.

The goal is to catalyze a culture shift in science by providing a platform for negative findings, which has significant value in the scientific process.

The initiative aligns with CVB’s belief that data transparency, reproducibility and rigor are key to advancing solutions for brain trauma, especially TBI.

Learn more: https://bit.ly/3aP7nnw

"The TBI imaging reference library will provide key information necessary to capitalize on these increasingly available analytical approaches to allow for imaging to help support decisions in the management of patients with mild TBI."

– James R. Stone, MD, PhD, NNL principal investigator, and Vice Chair of Research, UVA Department of Radiology and Medical Imaging

BRAIN Commons
Data sharing, harmonization, analytics, modeling and community

Harnessing the combined power of harmonized data, analytics and expertise to raise the bar for data sharing, modeling and team science.

The BRAIN Commons is a scalable, cloud-based platform for computational discovery designed for the brain health community. The BRAIN Commons provides secure access to a collaborative community, multimodal data and state-of-the-art analytic tools that facilitate rigorous and reproducible brain research including trauma and trauma-related research. Public launch in 2021.

Learn more: https://bit.ly/2ICWAaz